KKR and Impilo Announce Strategic Partnership Together With Management in Rare Disease Platform Immedica Pharma
2024年4月23日 - 2:00PM
ビジネスワイヤ(英語)
Investment funds managed by KKR, a leading global investment
firm, have agreed to acquire Immedica Pharma, a pharmaceutical
company headquartered in Stockholm, Sweden, focused on the
commercialization of medicines for rare diseases and specialty care
products. Existing owner, Nordic healthcare investment firm Impilo,
will reinvest to become an equal owner alongside KKR. The
transaction is subject to customary regulatory and closing
conditions.
KKR and Impilo will work together with Immedica’s management
team to support Immedica’s continued growth, including the launch
of the recently approved ultra-orphan drug Loargys, additional
pipeline assets, and continued in-licensing and M&A. The
company is also evaluating an expansion into the U.S. ahead of the
regulatory filing and potential approval of Loargys by the U.S.
FDA.
Immedica Pharma was established in 2018 by Impilo and an
experienced management team with a strong track record in launching
and commercializing orphan drugs across Europe. The business has
built up a portfolio and pipeline of drugs primarily within
haematology and oncology as well as genetic and metabolic diseases
for rare conditions with high unmet medical need and has quickly
expanded into an emerging leader in the European rare disease
space, with revenues of EUR 100m and annual growth of more than
50%. Growth catalysts have included a series of in-licensings and
acquisitions of drugs for orphan and niche conditions, as well as
the organic development of a pan-European and Middle Eastern launch
and commercialization organization with over 100 highly skilled
employees, supported by the corporate headquarters in
Stockholm.
Kugan Sathiyanandarajah, Partner and Head of KKR’s Health Care
Strategic Growth business in Europe, commented: “The Immedica team
is one of the best that we have encountered in a space that we have
been following for some time. We are deeply impressed by the
accomplishments of Immedica under Impilo’s ownership and the
establishment of a rare disease player with a highly promising
pipeline. We look forward to working with the management team
alongside Impilo to accelerate growth further.”
“KKR, with its experience in rare disease and specialty pharma
in Europe and the U.S., as well as its global presence and network,
is an ideal strategic partner for the next stage of Immedica’s
evolution. We are excited to continue our engagement in Immedica,
together with KKR, supporting management to realize our joint
vision of becoming a leading ultra-rare disease platform and making
medicines available to patients with high unmet medical needs,”
said Magnus Edlund, partner at Impilo.
“I am excited to continue our partnership with Impilo and
welcome KKR as a new strategic partner for the next step in
Immedica’s journey,” said Anders Edvell, CEO of Immedica. “Since
our inception in 2018 backed by Impilo, Immedica has made
significant strides towards becoming a leader in the rare disease
sector, providing innovative therapies to patients with severe
unmet medical needs. I look forward to working alongside both KKR
and Impilo as we further our mission, continue to build our
organisation, and expand our reach globally.”
KKR is investing in Immedica through its KKR Health Care
Strategic Growth Fund II, a $4.0 billion fund focused on investing
in high-growth health care companies. KKR has a long track record
of supporting health care companies globally, having invested
approximately $20 billion in the sector since 2004.
Impilo was advised by Morgan Stanley & Co. International as
financial advisor. Latham & Watkins served as lead legal
counsel, with Mannheimer Swartling advising on Swedish legal
matters, PwC advising on financial and tax matters, and BCG
assisting on commercial matters.
KKR was advised by BofA Securities as financial advisor. Gibson
Dunn served as lead legal counsel, with Setterwalls advising on
Swedish legal matters and Cooley advising on IP and licensing
matters, Alvarez & Marsal and PwC advising on financial and tax
matters, and Clearview Healthcare Partners assisting on commercial
matters.
About KKR
KKR is a leading global investment firm that offers alternative
asset management as well as capital markets and insurance
solutions. KKR aims to generate attractive investment returns by
following a patient and disciplined investment approach, employing
world-class people, and supporting growth in its portfolio
companies and communities. KKR sponsors investment funds that
invest in private equity, credit and real assets and has strategic
partners that manage hedge funds. KKR’s insurance subsidiaries
offer retirement, life and reinsurance products under the
management of Global Atlantic Financial Group. References to KKR’s
investments may include the activities of its sponsored funds and
insurance subsidiaries. For additional information about KKR &
Co. Inc. (NYSE: KKR), please visit KKR’s website at
www.kkr.com. For additional information about Global
Atlantic Financial Group, please visit Global Atlantic Financial
Group’s website at www.globalatlantic.com.
About Impilo
Impilo is a Nordic investment company focused solely on
investments in companies operating in the pharmaceutical, medical
technology, healthcare services and other health related
industries. Our starting point is that our portfolio companies must
contribute to a positive and sustainable development of the
societies and markets in which they operate in order to remain
successful in the long term. Impilo strives to increase value of
its investments through long-term active ownership. Impilo has a
well-diversified portfolio of healthcare investments and manages c.
EUR 1 billion of capital from leading Nordic and international
investors. Learn more about Impilo at www.impilo.se.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240422283835/en/
Immedica Linda Holmstr�m, Head of Communications
linda.holmstrom@immedica.com
KKR Nordics Fogel & Partners Ludvig Gauffin
kkr@fogelpartners.se
UK FGS Global Alastair Elwen KKR-Lon@FGSGlobal.com
Impilo Magnus Edlund, Partner magnus.edlund@impilo.se
KKR (NYSE:KKR)
過去 株価チャート
から 5 2024 まで 6 2024
KKR (NYSE:KKR)
過去 株価チャート
から 6 2023 まで 6 2024